Deltex Medical Group plc (AIM:DEMG)

Market Cap	455.05K
Revenue (ttm)	1.78M
Net Income (ttm)	-1.29M
Shares Out	1.90B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,651,950,635
Average Volume	42,258,399
Open	0.0400
Previous Close	0.0350
Day's Range	0.0240 - 0.0400
52-Week Range	0.0100 - 0.1970
Beta	0.63
RSI	30.97
Earnings Date	Mar 28, 2025

About Revance Therapeutics

Deltex Medical Group plc, together with its subsidiaries, manufactures, markets, and sells oesophageal doppler haemodynamic monitoring systems under the TrueVue name in the United Kingdom, the United States, and internationally. It offers oesophageal Doppler Probes that is used to guide fluid and drug interventions and haemodynamic monitoring; TrueVue Loops that plots aortic blood flow velocity and aortic blood pressure; High Definition Impedance Cardiography, a non-invasive cardiac function and fluid status monitoring system for awake patients...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2000
• Employees: 37
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: DEMG

Financial Performance

In 2023, Deltex Medical Group's revenue was 1.78 million, a decrease of -28.44% compared to the previous year's 2.48 million. Losses were -1.28 million, 12.0% more than in 2022.